近日,欧洲药品管理局(EMA)授予突破性抗癌药venetoclax治疗急性髓性白血病(AML)的孤儿药地位。之前,EMA已授予venetoclax治疗慢性淋巴细胞白血病(CLL)的孤儿药地位。而就在上个月,EMA已受理venetoclax单药治疗携带17p删除突变或TP53突变的慢性淋巴细胞白血病(CLL)的上市许可申请(MAA)。 在美国监管方面,FDA最近也授予venetoclax治疗AML的突破性药物资格和孤儿药地位,这也标志着venetoclax收获的FDA第3个突破性药物资格。2015年4月,FDA授予venetoclax单药治疗携带17p删除突变(del 17p)的复发性/难治性慢性淋巴细胞白血病(R/R CLL)的突破性药物资格。今年1月,FDA授予venetoclax联合罗氏抗癌药美罗华(Rituxan,通用名:rituximab,利妥昔单抗)治疗复发性/难治性慢性淋巴细胞白血病(R/R CLL)的突破性药物资格。另外,今年1月,FDA也授予venetoclax单药治疗既往已接受至少一种疗法的CLL(包括del 17p CLL)的新药申请(NDA)优先审查资格,这也意味着venetoclax很有可能在今年夏天就能获批在美国上市。 急性髓性白血病(AML)是一种进展迅速的血液和骨髓恶性肿瘤,也是成人群体中最常见的一种急性白血病类型。在欧洲,AML的年发病率大约为1/33000-1/25000。 venetoclax是一种口服的B细胞淋巴瘤因子-2(BCL-2)抑制剂,BCL-2在细胞凋亡(程序性细胞死亡)中发挥重要作用,可阻止一些细胞(包括淋巴细胞)的凋亡,并且在某些类型癌症中过度表达,与耐药性的形成相关。venetoclax旨在选择性抑制BCL-2的功能,恢复细胞的通讯系统,让癌细胞自我毁灭,达到治疗肿瘤的目的。 目前,一项大型研究正在进行,旨在探讨venetoclax单药及组合疗法治疗多种类型血癌,包括CLL、NHL、弥漫性大B细胞淋巴癌(DLBCL)、急性髓性白血病(AML)和多发性骨髓瘤(MM)。 New Drugs Online Report for venetoclax Information Generic Name: venetoclax Trade Name: Synonym: GDC-0199, ABT-199, RG7601 Entry Type: New molecular entity Development and Regulatory status UK: None EU: Phase II Clinical Trials US: Phase II Clinical Trials UK launch Plans: Available only to registered users Actual UK launch date: Comments Feb 16: EMA grants Orphan Drug Designation to venetoclax in AML; it has also been granted Orphan Drug Designation by the FDA [3]. 01/03/2016 17:49:21 Jan 16: FDA award venetoclax breakthrough status designation for use in combination with hypomethylating agents for patients with untreated AML who can´t take standard high-dose chemotherapy [2]. 01/02/2016 12:47:03 Trial or other data Deac 14: Abbvie initiate PII (NCT02287233) study to evaluate safety, efficacy and pharmacokinetics of venetoclax plus low-dose cytarabine regimen, in treatment-naïve patients with AML who are ineligible for anthrocycline-based induction chemotherapy [1]. 01/02/2016 12:42:26 Dec 14: Abbvie complete PII (NCT01994837) trial investigating the safety and efficacy of venetoclax in relapsed/refractory AML or as front-line therapy for patients who are unfit for intensive treatment [1]. 01/02/2016 12:40:29 References Available only to registered users Category BNF Category: Other antineoplastic drugs (08.01.05) Pharmacology: apoptosis stimulant; proto-oncogene protein c-bcl-2 inhibitor Epidemiology: AML affects < 1.2 in 10,000 people in the EU (equivalent to not more than 61,000 people) Indication: Acute myeloid leukaemia (AML) Additional Details: for those unfit for intensive chemotherapy Method(s) of Administration Oral Company Information Name: AbbVie US Name: AbbVie Further Information Anticipated commissioning route (England) NHSE High cost drug list? Awaiting Update Implications Available only to registered users |
欧盟授予venetoclax治疗急性髓性白血病简介:
近日,欧洲药品管理局(EMA)授予突破性抗癌药venetoclax治疗急性髓性白血病(AML)的孤儿药地位。之前,EMA已授予venetoclax治疗慢性淋巴细胞白血病(CLL)的孤儿药地位。而就在上个月,EMA已受理veneto ... 责任编辑:admin |
最新文章更多推荐文章更多热点文章更多
|